Macrogenics

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: 339

Market Cap: $215.1M

Website

Introduction: MacroGenics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of antibody-based therapeutics for the treatment of cancer. Its product pipeline includes Margetuximab, Flotetuzumab, Retifanlimab, Enoblituzumab, Tebotelimab, MGC018, MGD019, IMGC936, and MGD014 for infectious diseases. The company was founded by Scott E...

Clinical Trials

Safety Study of MGA271 in Refractory Cancer

Phase 1

Completed

Conditions: Prostate Cancer
Renal Cell Carcinoma
Head and Neck Cancer
Melanoma
Triple-negative Breast Cancer
Non-small Cell Lung Cancer
Bladder Cancer

Interventions: Biological: MGA271

First Posted Date: 2011-07-11

Last Posted Date: 2022-02-08

Lead Sponsor: MacroGenics

Target Recruit Count: 179

Registration Number: NCT01391143

Locations: 🇺🇸
Yale Cancer Center, New Haven, Connecticut, United States
🇺🇸
UCLA Hematology-Oncology Clinic, Los Angeles, California, United States
🇺🇸
Norton Cancer Institute, Louisville, Kentucky, United States

and more 9 locations

Expanded Access to MGAWN1 in Subjects With Suspected West Nile Neuroinvasive Disease; Suspected West Nile Virus Infection; or Substantial Accidental Exposure

Conditions: West Nile Virus Infection

First Posted Date: 2010-09-22

Last Posted Date: 2022-02-22

Lead Sponsor: MacroGenics

Registration Number: NCT01206504

Subcutaneous Administration of Teplizumab in Adults With Type 1 Diabetes

Phase 1

Terminated

Conditions: Type 1 Diabetes Mellitus

Interventions: Drug: teplizumab or placebo

First Posted Date: 2010-08-26

Last Posted Date: 2022-02-08

Lead Sponsor: MacroGenics

Target Recruit Count: 1

Registration Number: NCT01189422

Safety Study of MGAH22 in HER2-positive Carcinomas

Phase 1

Completed

Conditions: Gastric Cancer
Breast Cancer

Interventions: Biological: margetuximab

First Posted Date: 2010-06-22

Last Posted Date: 2022-10-19

Lead Sponsor: MacroGenics

Target Recruit Count: 66

Registration Number: NCT01148849

Locations: 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
🇺🇸
National Cancer Institute, Bethesda, Maryland, United States
🇺🇸
Sarah Cannon Research Institute, Nashville, Tennessee, United States

Safety Study of the Monoclonal Antibody Teplizumab (MGA031) in Subjects With Moderate or More Severe Psoriasis

Phase 1

Terminated

Conditions: Psoriasis

Interventions: Biological: teplizumab

First Posted Date: 2009-08-07

Last Posted Date: 2022-02-10

Lead Sponsor: MacroGenics

Target Recruit Count: 1

Registration Number: NCT00954915

Locations: 🇺🇸
University of Michigan Medical Center, Ann Arbor, Michigan, United States
🇺🇸
Oregon Health & Science University, Portland, Oregon, United States

Treatment of West Nile Virus With MGAWN1

Phase 2

Terminated

Conditions: Acute Flaccid Paralysis
Encephalitis
Meningitis
West Nile Neuroinvasive Disease
West Nile Virus Infection
West Nile Fever

Interventions: Biological: Placebo - normal saline
Biological: MGAWN1

First Posted Date: 2009-06-25

Last Posted Date: 2022-02-10

Lead Sponsor: MacroGenics

Target Recruit Count: 13

Registration Number: NCT00927953

Protege Encore Study- Clinical Trial of Teplizumab (MGA031) in Children and Adults With Recent-Onset Type 1 Diabetes Mellitus

Phase 3

Terminated

Conditions: Type 1 Diabetes Mellitus

Interventions: Drug: Placebo
Biological: Teplizumab 33.3% Herold Regimen
Biological: Teplizumab Herold Regimen
Biological: Teplizumab Curtailed Herold Regimen

First Posted Date: 2009-06-15

Last Posted Date: 2023-12-20

Lead Sponsor: MacroGenics

Target Recruit Count: 254

Registration Number: NCT00920582

Locations: 🇺🇸
University of Missouri - Columbia, Cosmopolitan Diabetes and Endocrinology, Columbia, Missouri, United States
🇺🇸
University Diabetes & Endocrine Consultants, Chattanooga, Tennessee, United States
🇺🇸
Research Institute of Dallas, Dallas, Texas, United States

and more 115 locations

Protege Extension Trial - Long Term Follow Up Trial for Subjects Who Completed the Protege Study (CP-MGA031-01)

Not Applicable

Terminated

Conditions: Type 1 Diabetes Mellitus

Interventions: Diagnostic Test: Blood samples for safety
Behavioral: Patient reported outcome questionnaires
Diagnostic Test: Analysis of T-cell subsets

First Posted Date: 2009-03-27

Last Posted Date: 2023-08-09

Lead Sponsor: MacroGenics

Target Recruit Count: 219

Registration Number: NCT00870818

Locations: 🇺🇸
Atlanta Diabetes Associates, Atlanta, Georgia, United States

Monoclonal Antibody RAV12 and Gemcitabine in Treating Patients With Metastatic Pancreatic Cancer

Phase 2

Terminated

Conditions: Pancreatic Cancer

Interventions: Biological: RAV12
Drug: Gemcitabine

First Posted Date: 2008-02-28

Last Posted Date: 2023-11-03

Lead Sponsor: MacroGenics

Target Recruit Count: 2

Registration Number: NCT00625586

Locations: 🇺🇸
MacroGenics, Incorporated, South San Francisco, California, United States
🇺🇸
Fox Chase Cancer Center - Philadelphia, Philadelphia, Pennsylvania, United States

A Trial to Evaluate the Safety of a Single Intravenous Infusion of MGAWN1 in Healthy Adults

Phase 1

Completed

Conditions: West Nile Virus

Interventions: Drug: MGAWN1
Other: Placebo

First Posted Date: 2007-08-13

Last Posted Date: 2022-02-22

Lead Sponsor: MacroGenics

Target Recruit Count: 40

Registration Number: NCT00515385

Locations: 🇺🇸
PAREXEL Phase 1 Unit, Baltimore, Maryland, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy